

## Immutep to Participate in Upcoming Investor Conferences

**SYDNEY, AUSTRALIA – April 02, 2025** – [Immutep Limited](#) (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces its management will present and participate in one-on-one meetings at the following investor conferences:

### **Jones Healthcare and Technology Innovation Conference**

Location: Las Vegas, NV  
Date: Wednesday, 9 April 2025  
Time: 4:30 pm ET

### **The Citizens Life Sciences Conference**

Location: New York, NY  
Date: Thursday, 8 May 2025  
Time: 1:00 pm ET

### **Jefferies Global Healthcare Conference**

Location: New York, NY  
Date: Wednesday & Thursday, 4 & 5 June 2025

Additional information for the Jefferies presentation will be made available closer to the conference on the [Events page](#) within the Investors & Media section of Immutep’s website.

### **About Immutep**

Immutep is a late-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit [www.immutep.com](http://www.immutep.com).

### **Australian Investors/Media:**

Catherine Strong, Sodali & Co.  
+61 (0)406 759 268; [catherine.strong@sodali.com](mailto:catherine.strong@sodali.com)

### **U.S. Media:**

Chris Basta, VP, Investor Relations and Corporate Communications  
+1 (631) 318 4000; [chris.basta@immutep.com](mailto:chris.basta@immutep.com)

This announcement was authorised for release by the CEO of Immutep Limited.